Report
EUR 13.70 For Business Accounts Only

Increased risk weighs on BML, penalising its rating down to Slightly Negative

The independent financial analyst theScreener just lowered the general evaluation of BML (JP), active in the Health Care Providers industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as moderately risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date January 21, 2022, the closing price was JPY 3,620.00 and its target price was estimated at JPY 3,081.33.
Underlying
BML Inc.

BML is mainly engaged in the provision of laboratory testing services including endocrine, plasma protein, biochemical, viral, immunological, hematological, bacteriological and histopathological tests as well as related services. Co.'s services include laboratory testing, "Frontier" and "Synphony" systems, and preventive medicine; electronic medical chart systems; food sanitation tests, safety assessment of genetically modified organisms, environment analysis, analysis of residual agricultural chemicals, dental tests, CRO, SMO, and clinical trials; and utilization of technology and information derived from the human genome study to provide gene analysis that is used in medical treatment.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch